Titin Gene Mutations and Radiotherapy in Rectal Cancer
Author Information
Author(s): Hengchang Liu, Jialiang Liu, Guan Xu, Zhao Zhixun, Cheng Pu, Chen Haipeng, Jiang Zheng, Wang Xishan
Primary Institution: Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center of Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Hypothesis
This study investigates the impact of Titin (TTN) gene mutations on radiotherapy sensitivity in rectum adenocarcinoma (READ) by examining changes in the tumour immune microenvironment.
Conclusion
TTN mutations can serve as biomarkers for enhanced radiotherapy sensitivity in READ by altering the tumour's immune microenvironment.
Supporting Evidence
- TTN mutations increase radiation sensitivity in rectal cancer by slowing cell proliferation and promoting apoptosis.
- Patients with TTN mutations and high densities of CD4+ and CD8+ T cells had longer disease-free survival.
- TTN mutations inhibit ANKRD1 expression, which is linked to DNA damage repair.
- TTN mutations enhance CD4/CD8 T-cell infiltration, improving anti-tumour immunity.
Takeaway
If a gene called Titin is changed in certain cancer cells, those cells might respond better to radiation treatment because they can help the immune system fight the cancer.
Methodology
The study used bioinformatics analysis, in vitro experiments with cell lines, and in vivo mouse models to assess the effects of TTN mutations on radiotherapy sensitivity and immune cell infiltration.
Limitations
The study's findings need confirmation in larger sample populations and multicenter studies.
Participant Demographics
Patients with locally advanced rectal cancer (LARC) who underwent neoadjuvant chemoradiotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website